Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PUR-WASH vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Sterile irrigation of body cavities, wounds, and surgical sites,Cleansing of wounds and burns,Rinsing of instruments and equipment,Hydration of tissues during surgical procedures
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
Terminal elimination half-life is 12-18 hours (mean 15 h). In patients with moderate renal impairment (Cr Cl 30-50 m L/min), half-life may extend to 24-30 hours; severe impairment (Cr Cl <30 m L/min) may prolong to >40 hours, requiring dose adjustment.
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
PUR-WASH is not metabolized; it is absorbed and excreted unchanged by the kidneys if administered intravenously or absorbed from wounds. When used topically or for irrigation, minimal systemic absorption occurs.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Primarily renal excretion of unchanged drug (85-90%), with 10-15% fecal elimination via biliary secretion.
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
Approximately 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein (AAG).
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
Vd = 0.3-0.5 L/kg, indicating moderate distribution into total body water; higher Vd observed in obesity (0.6 L/kg) due to lipophilicity.
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Oral: 95-100% (first-pass metabolism negligible); Intramuscular: 100%; Subcutaneous: 90-95% (site-dependent).
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No systemic absorption; not applicable.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No systemic absorption; not applicable.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
No systemic absorption; use as directed for wound irrigation per local protocol.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
No systemic absorption; use as directed for wound irrigation per local protocol.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
None
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
For external use only. Not for injection. Use only if solution is clear and container undamaged. Discard unused portion. Do not use for irrigation of closed cavities without adequate drainage. Monitor fluid and electrolyte balance when large volumes are used, especially in patients with renal impairment or cardiac failure. Prolonged contact with tissues may cause maceration.
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Hypersensitivity to any component. Do not use for irrigation of body cavities where absorption may lead to fluid overload or electrolyte disturbances without appropriate monitoring. Not for intravascular or intrathecal use.
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
None relevant as PUR-WASH is a topical irrigating solution with no systemic absorption.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly needed. No specific trimester risks have been identified.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
It is unknown whether PUR-WASH is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No pharmacokinetic studies have been performed in pregnant women. Currently, no dose adjustment is recommended for PUR-WASH during pregnancy, but caution is warranted due to limited data.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
PUR-WASH is a sterile, preservative-free irrigating solution indicated for wound cleansing and debridement. Use at room temperature to avoid thermal injury. Do not use for prolonged irrigation of closed body cavities due to risk of fluid absorption. For external wounds only; not for injection or ophthalmic use.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
Do not ingest or inject this solution; it is for external wound cleaning only.,Discard any unused portion after opening; do not reuse or store opened bottles.,Do not apply heat or microwave the solution to avoid burns.,Use within 24 hours of opening to maintain sterility.,If irritation or infection occurs, stop use and consult your healthcare provider.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PUR-WASH vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
PUR-WASH is a Irrigation Solution that works by PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PUR-WASH and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PUR-WASH is: Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PUR-WASH and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PUR-WASH is classified as Category C. PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly nee. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.